research Real-Life Effectiveness and Safety of Baricitinib in Patients with Severe Alopecia Areata: A 24-Week Italian Study
Baricitinib effectively reduces hair loss in severe alopecia areata with mild side effects.
Search
for
Sort by
Research
210-240 / 1000+ results 
research Among Scalp Non-Responder Patients with Eyebrow/Eyelash Regrowth in the First Year, Continued Treatment with Baricitinib Resulted in Meaningful Scalp Responses for Patients with Severe Alopecia Areata
Continued baricitinib treatment leads to significant scalp hair regrowth in severe alopecia areata patients.
research Androgenic Alopecia Is Associated With More Severe Lower Urinary Tract Symptoms Secondary to Benign Prostatic Hyperplasia
People with hair loss may have worse urinary symptoms due to an enlarged prostate.
research Dermatologic Manifestations of Patients With Severe and Non-Severe COVID-19 Infection: A Cross-Sectional Study
COVID-19 can cause various skin issues, with some linked to how severe the illness is.
research Baricitinib Withdrawal and Retreatment in Patients With Severe Alopecia Areata
Continuous baricitinib is needed to keep hair regrowth in severe alopecia areata.
research A Case of Delusional Parasitosis Secondary to Severe Iron Deficiency Anemia in a Tertiary Care Hospital: An Area for Clinical Vigilance
Iron deficiency can cause psychiatric symptoms that improve with proper treatment.
research Contemporaneous Onset of Systemic Lupus Erythematosus and Severe Eating Disorder: Neither the Chicken Nor the Egg
Hormonal changes and social stress may link lupus and eating disorders in teens.
research Baricitinib Therapy for Moderate to Severe Alopecia Areata: A Retrospective Review of 95 Japanese Patients
research Distribution of SALT Scores by Therapeutic Response in Patients with Severe Alopecia After 52 Weeks of Baricitinib Therapy
Baricitinib therapy helped many patients with severe alopecia regrow hair after 52 weeks.
research Outcomes of Down-Titration in Patients With Severe Scalp Alopecia Areata Treated With Baricitinib: An Update Through Week 152 From BRAVE-AA2
Reducing the dose of Baricitinib to 2mg still helped over half of the patients with severe scalp alopecia maintain their hair regrowth after two years.
research Pilonidal Sinus Disease Is Associated With Severe Hidradenitis Suppurativa in a Spanish Cohort
Pilonidal sinus disease is linked to more severe hidradenitis suppurativa.
research Real-Life Effectiveness and Tolerance of Baricitinib for the Treatment of Severe Alopecia Areata with 1-Year Follow-Up Data
Baricitinib effectively regrows hair in most people with severe alopecia, especially those with patchy hair loss, but hair may fall out again if treatment stops.
research Early Real-World Experience With Baricitinib in the Treatment of Severe Alopecia Areata
Baricitinib shows promise in treating severe hair loss.
research Efficacy and Safety of Proxalutamide in Severe or Critically Ill COVID-19 Patients: Study Protocol for an Exploratory Trial
The trial will test if proxalutamide is safe and effective in reducing death in severe COVID-19 patients.
research Efficacy and Safety of Baricitinib in Managing Severe Alopecia Areata: A 6-Month Real-World Experience
Baricitinib was effective and safe for severe hair loss treatment over 6 months.
research Multidisciplinary Treatment of Transgender Woman With Severe Gender Dysphoria and Comorbid Psychiatric Disorders - Case Report
The treatment helped a transgender woman stop drinking, improved her mental health, and reduced her gender dysphoria.
research Efficacy of Baricitinib in Patients With Different Degrees of Severe Alopecia Areata: 52-Week Results From BRAVE-AA1 and BRAVE-AA2
Baricitinib was effective in treating severe and very severe alopecia areata after 52 weeks.
research Cryo-EM and Molecular Dynamics of TRPV3 Channel in Activated State Reveal Structural Features Implicated in Severe Itch and Hyperkeratosis
The TRPV3 channel structure changes linked to severe itch and hyperkeratosis were identified using cryo-EM.
research A Brazilian Case of IFAP Syndrome With Severe Congenital Ichthyosis and Limb Malformations Caused by a Rare Variant in MBTPS2
A Brazilian male with IFAP syndrome has a unique genetic variant causing his condition.
research Complete Hair Regrowth in a Young Male With Severe Atopic Dermatitis and Alopecia Areata After Dupilumab: Probably More Than a Coincidence
Dupilumab led to complete hair regrowth and improved skin condition in a young man with severe eczema and hair loss.
research Re-Discovery of Trichophyton Bullosum in North Africa as a Cause of Severe Dermatophytosis in Donkeys
Trichophyton bullosum has been found causing severe skin infections in donkeys in North Africa for the first time since 1933.
research Compound Heterozygous Mutations in Forkhead Box N1 (FOXN1) Lead to Severe Immunodeficiency but Normal Hair and Nail Development in Patients
Mutations in the FOXN1 gene cause severe immune issues but don't affect hair and nails.
research Reply to: Tofacitinib for the Treatment of Severe Alopecia Areata and Variants
More extensive trials are needed to understand tofacitinib's role in treating severe hair loss.
research Supplementary Material for: Janus Kinase Inhibitors for the Treatment of Severe Alopecia Areata: An Open-Label Comparative Study
Ruxolitinib and tofacitinib are effective and safe for treating severe alopecia areata.
research Tofacitinib for the Treatment of Severe Alopecia Areata and Variants: A Retrospective Cohort Study of 90 Patients
Tofacitinib is effective and safe for treating severe alopecia areata and related conditions.
research Patients with Compound Heterozygous Mutations in Forkhead Box N1 Have Severe Immunodeficiency While Maintaining Normal Skin and Hair Development
Patients with certain FoxN1 gene mutations have severe immune issues but normal skin and hair.
research A 9-Month-Old Infant with Severe Scalp Dermatosis
The infant likely has Hay-Wells syndrome and needs genetic testing and heart screening.
research Oral Ruxolitinib Induces Hair Regrowth in Patients with Moderate-to-Severe Alopecia Areata
Ruxolitinib effectively regrows hair in most patients with severe hair loss.
research Tamsulosin Treatment for Benign Prostatic Hyperplasia and Risk of Severe Hypotension in Men Aged 40-85 Years in the United States: Risk Window Analyses Using Between and Within Patient Methodology
Tamsulosin for enlarged prostate may increase the risk of severe low blood pressure, especially when starting or restarting the medication.
research Zinc Deficiency Associated with Hypothyroidism: An Overlooked Cause of Severe Alopecia
Zinc supplements may be needed to treat hair loss in hypothyroidism.